Aprepitant

• A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Pending
  2025-522204-24-00 Phase II 4 countries Eli Lilly & Co.
• A Randomized, Placebo-controlled, Parallel Phase 2a Dose-ranging Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-0… Pending
  2025-523058-16-00 Phase II 3 countries Hoth Therapeutics Inc.
• Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting
  2022-502983-19-00 Phase II 5 countries K-Group Beta Inc.
• A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting
  2024-511309-47-00 Phase II 13 countries Karyopharm Therapeutics Inc.
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma… Recruiting
  2024-512827-36-00 Phase II 1 country Unicancer
• OPEN-LABEL EXTENSION STUDY TO ASSESS THE SAFETY AND LONG-TERM EFFECTIVENESS OF ORALLY ADMINISTERED EFAVIRENZ IN PATIENTS DIAGNOSED WITH ADUL… Ended
  2023-505832-36-01 Phase II 1 country Bellvitge University Hospital; Fundacio Institut D'Investigacio Biomedica De Bel…
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• The efficacy of aprepitant for the prevention of postoperative nausea and vomiting after bariatric surgery. Ended
  2023-508849-40-00 Phase IV 1 country University Of Tartu
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended
  2023-506139-13-00 Phase III 13 countries Karyopharm Therapeutics Inc.
• A clinical study of pembrolizumab with other study treatments in people with refractory lung cancer (MK-3475-B98) Ended
  2023-507687-38-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
• A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Ended
  2023-507324-23-00 Phase II 3 countries K-Group Beta Inc.
• DAVINCY trial: optimal Duration of (fos)Aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind p… Ended
  2024-517846-32-00 Phase III 1 country Prinses Maxima Centrum voor Kinderoncologie B.V.

Showing 1–13 of 13 trials